Reserve testosterone monotherapy for men with mild erectile dysfunction and an absolute demonstration of hypogonadism; otherwise combine testosterone therapy with a PDE5 inhibitor. Triggered when a clinician managing erectile dysfunction asks whether testosterone alone is sufficient or a PDE5 inhibitor should be added.
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill icsm-tt-monotherapy-mild-ed --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Icsm Tt Monotherapy Mild Ed?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-icsm-tt-monotherapy-mild-ed)More formats (shields.io, HTML) on the badges page.
---
name: icsm-tt-monotherapy-mild-ed
description: Reserve testosterone monotherapy for men with mild erectile dysfunction and an absolute demonstration of hypogonadism; otherwise combine testosterone therapy with a PDE5 inhibitor. Triggered when a clinician managing erectile dysfunction asks whether testosterone alone is sufficient or a PDE5 inhibitor should be added.
---
# Reserve testosterone monotherapy for mild erectile dysfunction with proven hypogonadism
## STEP 1 — Gather Information
- Confirm erectile dysfunction and assess severity (mild vs moderate/severe) using IIEF-5 or clinical judgment.
- Document symptoms suggestive of hypogonadism (low libido, decreased morning erections, fatigue).
- Obtain two morning total testosterone (tT) measurements (fasting, 07:00–11:00 h) using a reliable assay; absolute demonstration of hypogonadism = tT <12 nmol/L on both occasions.
- Note any prior use of PDE5 inhibitors and response.
## STEP 2 — Rule In / Rule Out
Is the erectile dysfunction mild?
- **No** → Testosterone monotherapy not appropriate; proceed to combination therapy or PDE5 inhibitor alone based on hypogonadism status.
- **Yes** → Continue to assess hypogonadism.
## STEP 3 — Classify or Stratify
Is there an absolute demonstration of hypogonadism (tT <12 nmol/L on two morning samples)?
- **Yes** → Candidate for testosterone monotherapy.
- **No** → Testosterone monotherapy not indicated; consider combining testosterone therapy with a PDE5 inhibitor.
## STEP 4 — Decide
- If mild ED **and** absolute hypogonadism → Initiate testosterone monotherapy (e.g., transdermal gel targeting mid-normal tT).
- Otherwise → Prescribe testosterone therapy combined with a PDE5 inhibitor (or PDE5 inhibitor alone if eugonadal) and reassess erectile function in 3 months.
## Clinical Guardrails / Mimics / Pitfalls
- Do not use testosterone monotherapy in men without two‑step approach: never start monotherapy without confirming low tT on two separate occasions.
- Avoid monotherapy in moderate or severe ED; efficacy is limited and combination is preferred.
- Monitor hematocrit, PSA, and symptoms; withdraw if hematocrit >54% or adverse events occur.
- Do not rely on monotherapy to treat depression, obesity, or metabolic disease alone.
## Concrete Clinical Example
A 58‑year‑old man reports mild erections (IIEF‑5 16) and low libido. Morning tT is 10 nmol/L on two separate visits. He asks if testosterone alone will help. Since ED is mild and hypogonadism is proven, start testosterone gel 5 mg daily. At 3‑month follow‑up, IIEF‑5 improves to 20; if further improvement desired, add sildenafil 50 mg PRN.
**Source:** International Consultation on Sexual Medicine (ICSM) 2024, Box2 Recommendation 8, 2025, https://doi.org/10.1093/sxmrev/qeaf036

Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!